91307CAE2
United Therapeutics Corporation
Could not find a ticker for this position, may be a filing error
A maker of medicines for rare lung conditions such as pulmonary arterial hypertension, sold under brands like Remodulin and Tyvaso. Founder Martine Rothblatt launched the company in 1996 after her young daughter was diagnosed with the disease, turning a personal fight into a career. The firm is also known for a futuristic goal: gene-edited pig organs for human transplants, an approach that has made it a familiar name in xenotransplantation.
CONVERTIBLEUnderlying: UTHRCUSIP: 91307CAE2HealthcareUS1 derivative reporter
1.00% Convertible Senior Notes due 2016-09-15 (Rule 144A)
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
